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PVIEWPOINT
Treatment of Heart Failure With Normal Ejection Fraction
An Inconvenient Truth!
Walter J. Paulus, MD, PHD, Joris J. M. van Ballegoij, BSC
Amsterdam, the Netherlands
Despite use of similar drugs, outcomes of recent heart failure (HF) trials were frequently neutral in heart failure
with normal left ventricular ejection fraction (HFNEF) and positive in heart failure with reduced left ventricular
ejection fraction (HFREF). The neutral outcomes of HFNEF trials were often attributed to deficient HFNEF patient
recruitment with inclusion of many HFREF or noncardiac patients. Patient recruitment criteria of 21 HFNEF trials
were therefore reviewed in reference to diagnostic guidelines for HFNEF. In the 4 published sets of guidelines, a
definite diagnosis of HFNEF required the simultaneous and obligatory presence of signs and/or symptoms of HF
and evidence of normal systolic left ventricular (LV) function and of diastolic LV dysfunction. In 3 of 4 sets of
guidelines, normal systolic LV function comprised both a left ventricular ejection fraction (LVEF) 50% and an
absence of LV dilation. Among the 21 HFNEF trials, LVEF cutoff values ranged from 35% to 50%, with only 8
trials adhering to an LVEF 50%. Furthermore, only 1 trial specified a normal LV end-diastolic dimension as an
enrollment criterion and only 7 trials required evidence of diastolic LV dysfunction. Nonadherence to diagnostic
guidelines induced excessive enrollment into HFNEF trials of HF patients with eccentric LV remodeling and ischemic
heart disease compared with HF patients with concentric LV remodeling and arterial hypertension. Nonadherence to
guidelines also led to underpowered HFNEF trials with a low incidence of outcome events such as death or HF hospi-
talizations. Future HFNEF trials should therefore adhere to diagnostic guidelines for HFNEF. (J Am Coll Cardiol 2010;
55:526–37) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.067l
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ls a result of modern evidence-based heart failure (HF)
herapy, the prognosis of patients with heart failure with
educed left ventricular ejection fraction (HFREF) im-
roved progressively over the past 3 decades. Conversely,
espite frequent use of similar pharmacological agents, the
rognosis of patients with heart failure with normal left
entricular ejection fraction (HFNEF) remained unaltered
ver the same time period (1). Contrasting efficacy of
omparable pharmacological agents inHFREF andHFNEFwas
onvincingly demonstrated by the neutral outcome of the
ecent I-PRESERVE (Irbesartan in Heart Failure with
reserved Systolic Function) trial (2), which assigned
FNEF patients to the angiotensin II receptor blocker
ARB) irbesartan or placebo, and by the positive outcome
f the earlier CHARM (Candesartan in Heart Failure–
ssessment of Mortality and Morbidity)-Alternative trial
3), which assigned HFREF patients to the ARB candesar-
an or placebo. Contrasting efficacy has also been reported
or the prevention of HFNEF or HFREF. In hypertensive
atients of the ALLHAT (Antihypertensive and Lipid-
owering Treatment to Prevent Heart Attack Trial) study (4),
rom the Institute for Cardiovascular Research Vrije Universiteit, VU University
edical Center Amsterdam, Amsterdam, the Netherlands. Supported by grant
006B035 from the Dutch Heart Foundation.m
Manuscript received April 28, 2009; revised manuscript received June 12, 2009,
ccepted June 15, 2009.isinopril was inferior to chlorthalidone for preventing new-
nset HFNEF but not for new-onset HFREF.
The discordant outcomes of similar pharmacological
herapy in HFNEF and HFREF could suggest that the
ignal transduction cascades driving myocardial remodeling
iffer in HFNEF and HFREF (5). The left ventricular (LV)
tructure and myocardial ultrastructure indeed argue in favor
f unequal myocardial signal transduction cascades in both
FNEF and HFREF. Patients with HFNEF have concen-
ric LV remodeling with high LV mass/volume ratio in
ontrast to patients with HFREF, who have eccentric LV
emodeling with low LV mass/volume ratio (6–9). Myo-
ardial ultrastructure follows a similar trend, with cardio-
yocyte hypertrophy in HFNEF and loss of myofilaments
n HFREF (9). Because of these divergences of myocardial
tructure and ultrastructure in HFNEF and HFREF, an
nequal clinical response to similar pharmacological agents
s not surprising.
Nevertheless, many concerns persist that mainly method-
logical issues involving identification and recruitment of
FNEF patients account for the neutral outcomes of HFNEF
rials. In the presence of a normal left ventricular ejection
raction (LVEF), the diagnosis of HF is less evident. Inclusion
f patients whose complaints of low exercise tolerance and
yspnea are caused by noncardiac causes is therefore more
ikely in HFNEF than in HFREF trials. The present review of
ajor HFNEF trials addresses these concerns and focuses on
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February 9, 2010:526–37 Treatment of HFNEFatient recruitment in reference to published guidelines for the
iagnosis of HFNEF. In HFNEF trials, criteria used for
atient recruitment were highly variable, disregarded diagnos-
ic guidelines, and were therefore frequently unsatisfactory.
his “inconvenient truth” unfortunately leads to a persistent
ncertainty of whether the neutral outcomes of these trials
esulted from methodological flaws or from specific patho-
hysiological features characterizing HFNEF.
iagnostic Guidelines for HFNEF
riginally HFNEF was described as diastolic HF (10).
hen awareness grew that diastolic LV dysfunction was
ot unique to diastolic HF but also was present in HF with
ystolic LV dysfunction, the term diastolic HF was largely
bandoned and was replaced by the terms HF with pre-
erved LVEF (11) or HFNEF (12). Both terms, however,
lso have their shortcomings. The notion of a preserved
VEF implies knowledge of a pre-existing LVEF, which is
sually absent, and the exact range of a normal LVEF is
ard to define (13,14). The present review, which relates
ecruitment criteria of trials to diagnostic guidelines, prefers
he use of the term HFNEF because formal diagnostic
uidelines were only published for diastolic HF (10,15,16)
nd HFNEF (5).
Four sets of guidelines have so far been published for the
iagnosis of HFNEF. They all require the simultaneous and
bligatory presence of signs and/or symptoms of HF,
vidence of normal systolic LV function, and evidence of
iastolic LV dysfunction (Table 1). The first set of guide-
ines was provided by the Working Group on Myocardial
unction of the European Society of Cardiology (10). The
riteria used were signs or symptoms of HF, an LVEF
45%, a left ventricular end-diastolic volume index
LVEDVI) 102 ml/m2, and evidence of diastolic LV
ysfunction provided by cardiac catheterization (pulmonary
apillary wedge pressure [PCWP] 12 mm Hg or left
entricular end-diastolic pressures [LVEDP] 16 mm Hg)
r by mitral or pulmonary venous Doppler flow velocity
ecordings. A second set of guidelines was provided by the
ational Heart, Lung, and Blood Institute Framingham
eart Study and combined signs and symptoms of HF,
ormal LVEF (50%), and invasive evidence of diastolic
V dysfunction to provide 3 different levels of evidence for
FNEF (15). Definite HFNEF required the 3 conditions
o be satisfied and the LVEF data to be procured within
2 h of the congestive HF episode. Probable and possible
FNEF required the first 2 conditions to be satisfied and
he LVEF data to be procured within 72 h for probable
FNEF and later than 72 h for possible HFNEF. The
mphasis placed on timely acquisition of the LVEF data
as subsequently shown to be unwarranted because patients
ith hypertensive pulmonary edema had normal and com-
arable LVEF at hospital admission and 3 days later at
ecompensation (17). A third set of guidelines was proposed
y Yturralde and Gaasch from the Lahey Clinic (16). For phe definite diagnosis of HFNEF,
hey also require the same 3 con-
itions to be satisfied as in the 2
revious sets of guidelines. They
mplement their assessment with a
coring system of major criteria
nd confirmatory evidence and use
V hypertrophy and left atrial
LA) enlargement as substitutes
or catheterization or Doppler ev-
dence of diastolic LV dysfunction.
inally, the last set of guidelines
as recently published by the
eart Failure and Echocardiogra-
hy Associations of the European
ociety of Cardiology (5). This set
f guidelines was the first to con-
ider the use in HFNEF of tissue
oppler imaging (TDI) and natri-
retic peptides (NP). The diag-
osis of HFNEF required signs
r symptoms of HF, an LVEF
50%, an LVEDVI 97 ml/m2,
nd evidence of diastolic LV dys-
unction. Only cardiac catheteriza-
ion and TDI could provide stan-
alone evidence of diastolic LV
ysfunction, whereas NP needed
o be implemented with TDI, mi-
ral flow velocity Doppler, or mea-
ures of LA size or LV mass.
hen comparing these 4 sets of
iagnostic guidelines, it becomes
vident that the mere presence of
igns or symptoms of HF and a
ormal LVEF never sufficed to
rmly establish the diagnosis of
FNEF, which always required
dditional evidence of diastolic LV
ysfunction, LA size, or LV mass.
The emphasis on diastolic
V dysfunction in the pub-
ished sets of diagnostic guidelines does not imply dia-
tolic LV dysfunction to be the sole mechanism under-
ying HFNEF. Numerous other mechanisms have
ecently been identified and could be equally important
18). These mechanisms include reduced mitral annular
hortening velocity (19), depressed LV longitudinal and
adial deformation (20,21), ventriculovascular coupling
22), chronotropic incompetence (23), LA dilation (24),
olume overload (25), and pulmonary arterial hyperten-
ion (26). In the normal heart, systolic motion of the
itral annulus toward the apex and systolic LV twist help
o suck in blood during early diastole through the sudden
elease of stored energy. In HFNEF patients, this inter-
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AGE  advanced glycation
end product
ARB  angiotensin II
receptor blocker
cGMP  guanosine 3=,5=-
cyclic monophosphate
HF  heart failure
HFNEF  heart failure with
normal left ventricular
ejection fraction
HFREF  heart failure with
reduced left ventricular
ejection fraction
LA  left atrial
LBBB  left bundle branch
block
LV  left ventricle/
ventricular
LVEDP  left ventricular
end-diastolic pressure
LVEDVI  left ventricular
end-diastolic volume index
LVEF  left ventricular
ejection fraction
MMP  matrix
metalloproteinase
NP  natriuretic peptide
PCWP  pulmonary
capillary wedge pressure
PDE5 
phosphodiesterase-5
PFR  peak filling rate
PKG  protein kinase G
TDI  tissue Doppler
imaging
TIMP  tissue inhibitors of
matrix metalloproteinaselay between systolic and diastolic LV function is dis-
r
s
e
e
N
v
d
b
p
o
H
s
R
w
t
i
s
o
(
c
p
H
n
O
T
p
d
h
V
c
O
A
b
v
e hypertro
P
E
C
m
528 Paulus and van Ballegoij JACC Vol. 55, No. 6, 2010
Treatment of HFNEF February 9, 2010:526–37upted with concomitant elevation of LV filling pres-
ures, especially during exercise (12). Effective arterial
lastance, a global measure of arterial stiffness, and
nd-systolic LV elastance are typically elevated in HF-
EF patients. Because of these elevated arterial and
entricular elastances, limited changes in LV end-
iastolic volume induce exaggerated swings in systolic
lood pressure. Intermittent high arterial systolic blood
ressure because of these swings greatly increases cardiac
xygen consumption (22). At similar exercise workloads,
FNEF patients have less increase in heart rate and less
ystemic vasodilation than matched control subjects (23).
estoring chronotropic competence in HFNEF patients
ith rate-adaptive pacing is currently being assessed in
he RESET (Restoration of Chronotropic Competence
n Heart Failure Patients with Normal Ejection Fraction)
verview of Diagnostic Guidelines for HFNEFTable 1 Overview of Diagnostic Guidelines for HFNEF
ESC
1998 (10)
NHL
2000
HF signs and symptoms
(other criteria)
Present Pres
Normal LV systolic function LVEF 45%
LVEDVI 102 ml/m2
LVEF 
within 7
episo
LV diastolic dysfunction LVEDP 16 mm Hg
PCW 12 mm Hg
E/A 0.5
DT 280 ms
IVRT 105 ms
PVV 0.35 m/s
Ard-Ad 20 ms
LVEDP 1
PCW 12
ll 4 sets of guidelines require the simultaneous presence of HF signs and/or symptoms and norma
ut criteria for diastolic LV dysfunction are variable.
A  atrial wave mitral flow velocity; Ad  duration of atrial wave mitral flow velocity; Ard  dur
elocity; E=  early tissue Doppler lengthening velocity; HF  heart failure; HFNEF  heart fail
nlargement; LV  left ventricular; LVEF  left ventricular ejection fraction; LVH  left ventricular
VV  pulmonary vein atrial maximal velocity.
nrollment Criteria of Large HFNEF Outcome TrialsTable 2 Enrollment Criteria of Large HFNEF Outcome Trials
V-HeFTII
Enalapril
2 years (27)
DIG
Digoxin
37 months (31)
CHARM
Candesa
3 years (
HF signs and symptoms
(other criteria)
Present
(VO22)
Present Presen
Normal LV systolic function LVEF 35%
CTR 0.55
LVEDDI 2.7 cm/m2
LVEF 45% LVEF 4
LV diastolic dysfunction — — —
Positive outcomes Mortality 40% Hospitalizations HospitalizaTR  cardiothoracic ratio; DT  deceleration time; LVEDDI  left ventricular end-diastolic dimension ind
otion index; WT  wall thickness; other abbreviations as in Table 1.tudy. Finally, LA dilation and dysfunction (24); volume
verload because of renal insufficiency, anemia, or obesity
25); and pulmonary hypertension with a pre-capillary
omponent (26) can all contribute to HF in HFNEF
atients. Future refinements to diagnostic guidelines for
FNEF will probably incorporate criteria based on these
ondiastolic mechanisms.
verview of HFNEF Trials
able 2 shows all major large outcome trials that have been
erformed so far in HFNEF patients. An outcome trial is
efined as a large-scale, long-duration clinical trial with
ard end points, including morbidity and mortality. The
-HeFT II (Vasodilator in Heart Failure Trial II), which
ompared enalapril with the combination of hydralazine and
HFNEF Guidelines
Year Published (Ref. #)
LAHEY
2005 (16)
ESC
2007 (5)
Present Present
LVEF 50%
LVEDVI 97 ml/m2
LVEF 50%
LVEDVI 97 ml/m2
Hg
g
LVEDP 16 mm Hg
PCW 12 mm Hg
E/A 0.5
DT 280 ms
IVRT 105 ms
LAE
LVH
LVEDP 16 mm Hg
PCW 12 mm Hg
E/E= 15
E/E= 8  NT-proBNP 220 pg/
ml
tolic function and diastolic LV dysfunction. Criteria for normal LV systolic function are comparable,
reverse pulmonary vein atrial systole flow velocity; DT  deceleration time; E  early mitral flow
normal left ventricular ejection fraction; IVRT  isovolumic relaxation time; LAE  left atrial
phy; NT-proBNP  N-terminal pro–B-type natriuretic peptide; PCW  pulmonary capillary wedge;
Trial
Compound
Duration (Ref. #)
SENIORS
Nebivolol
12 months (37)
PEP-CHF
Perindopril
2.1 years (38)
I-PRESERVE
Irbesartan
49.5 months (2)
Present Present
(3/9 criteria including prior MI)
Present
LVEF 35% LVEF 40%
WMI 1.4
LVEF 45%
— WT 13 mm
IVRT 105 ms
E/A 0.5
DT 280 ms
LA diameter 25 mm/m2
LAE
LVH
Mortalityhospitalizations
14%
Hospitalizations and symptoms
at 1 yr follow-up
—BI
(15)
ent
50%
2h HF
de
6 mm
mm H
l LV sys
ation of
ure with-P
rtan
33)
t
0%
tionsex; MI  myocardial infarction; VO2  maximal oxygen consumption during exercise; WMI  wall
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February 9, 2010:526–37 Treatment of HFNEFsosorbide dinitrate, performed a subanalysis of patients
ith LVEF 35% and reported a beneficial effect on
ortality and incidence of ventricular tachycardia (27). This
avorable response to enalapril probably related to reduced
ccentric LV remodeling because the enrollment criteria of
-HeFT II explicitly required evidence of LV dilation.
educed eccentric LV remodeling is, however, of question-
ble relevance to most HFNEF patients, who are more
ikely to present with progressive concentric LV remodeling
6–9). Based on data from large HFNEF registries, con-
entric LV remodeling in HFNEF relates to comorbidities
ther than prior myocardial infarction, such as arterial
ypertension (80% of patients), diabetes (30% of patients),
nd excess body weight (80% of patients) (28–30). These
FNEF registries, however, also enrolled their patients
ithout requiring evidence of diastolic LV dysfunction. The
igitalis Investigation Group studied outcomes of treat-
ent with digoxin both in patients with reduced LVEF
main trial) (31) and in patients with preserved LVEF
ancillary trial) (32). In both trials, digoxin had no effect on
he mortality of chronic HF patients in normal sinus rhythm
ut reduced their need for worsening HF hospitalizations.
pecific clinical characteristics of the patients recruited for
he ancillary trial have been reported (32), and again
uggested a high prevalence of eccentric LV remodeling
ecause 49% of patients had suffered a prior myocardial
nfarction. The CHARM-Preserved trial randomized 3,023
atients between candesartan and placebo (33). The
HARM-Preserved trial failed to demonstrate a significant
ffect on cardiovascular death, but fewer HF hospitaliza-
ions in the candesartan-treated patients were observed.
gain, HF was mainly of ischemic origin (56% of patients),
ith a history of prior myocardial infarction, percutaneous
oronary intervention, and coronary artery bypass grafting
resent in 45%, 17%, and 21% of patients, respectively.
redominant eccentric LV remodeling in the CHARM-
reserved trial was demonstrated by the CHARMES (Can-
esartan in Heart Failure Reduction in Mortality Echocar-
iographic Substudy) trial (34), which revealed an LV mass
ndex in the candesartan-treated group of 111  35 g/m2.
his value was within the normal reference range for men
49 to 115 g/m2) (35), who composed 66% of the
HARMES substudy population. The SENIORS (Study
f Effects of Nebivolol Intervention on Outcomes and
ehospitalization in Seniors With Heart Failure) used the
eta-blocker nebivolol in elderly HF patients over 70 years
f age and observed a 14% reduction in primary outcomes
all-cause mortality and cardiovascular hospital admission)
36). The beneficial effect on primary outcome did not differ
etween patients with LVEF 35% and those with LVEF
35%, but favorable effects on LV end-systolic volume and
VEF were limited to nebivolol-treated patients with
VEF 35% (37). The PEP-CHF (Perindopril in Elderly
eople with Chronic Heart Failure) study was the first
ajor randomized controlled trial on the use of angiotensin-
onverting enzyme inhibitors (ACEI) in HFNEF patients (38). st compared perindopril 4 mg daily with placebo in elderly
atients (70 years old) with a diagnosis of HF, an LVEF
40%, minimal impairment of segmental LV wall motion,
chocardiographic evidence of LA dilation or LV hypertro-
hy, and abnormal LV filling kinetics on mitral flow velocity
oppler. The study showed no difference in mortality and
F hospitalizations. Premature withdrawal of many pa-
ients after 1 year could have contributed to the neutral
utcome because an interim analysis at 1 year of follow-up
howed a significant reduction (p  0.033) in HF hospi-
alizations. Criteria for patient enrollment into the PEP-
HF study, however, also had shortcomings. The diagnosis
f symptomatic HF was linked to 9 criteria, of which 3
eeded to be satisfied. These criteria comprised, among
thers, prior myocardial infarction and a cardiothoracic ratio
0.55. As a result, 39% of enrolled patients had coronary
rtery disease, and eccentric LV remodeling again became
n important confounder. The I-PRESERVE trial is so far
he largest reported trial for HFNEF. It enrolled 4,128
atients and randomly assigned them to irbesartan or
lacebo (2). Mortality or rates of hospitalizations for car-
iovascular causes were not improved by irbesartan. Almost
alf of the patients were recruited because of HF hospi-
alization within the previous 6 months. The other half
as recruited because they were symptomatic and satis-
ed at least 1 of the following criteria: pulmonary
ascular congestion on chest X-ray film, echocardio-
raphic evidence of LV hypertrophy or of LA enlarge-
ent, and electrocardiographic evidence of LV hypertro-
hy or of left bundle branch block (LBBB). Inclusion of
BBB is worrisome because LBBB is more prevalent in
atients with HFREF than with HFNEF. Nevertheless,
he clinical characteristics of the I-PRESERVE study
opulation suggest less eccentric LV remodeling than in
he previous trials, as there was a lower prevalence of
rior myocardial infarction (24%) and a higher prevalence
f arterial hypertension (88%) and of electrocardio-
raphic evidence of LV hypertrophy (30%). Echocardio-
raphic measures of LV mass, LVEDVI, and LV mass/
olume ratio have not yet been reported and could further
ubstantiate predominant concentric LV remodeling in
he I-PRESERVE study population.
In HFNEF registries, the effect of pharmacological treat-
ent on mortality was variable, as evident from Table 3. In
cohort of HFNEF patients prospectively followed up for
5 months after hospital discharge, prescription of a beta-
locker resulted in a 43% mortality reduction (39). In a
imilar 5-year registry of HFNEF patients surviving a first
F hospitalization, the 5-year mortality risk also decreased
y 30% with ACEI treatment (40). In a community-based
egistry of HF patients (the COHERE [Carvedilol Heart
ailure Registry] study), the benefit of carvedilol therapy
as less, with a 6% mortality reduction for patients with an
VEF 40% (41). In this registry, the mortality reduction
id not differ across the range of LVEF, but functional
tatus and need for hospitalizations showed less improve-
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Treatment of HFNEF February 9, 2010:526–37ent when LVEF exceeded 40%. Finally, in the
PTIMIZE-HF (Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients With Heart Failure)
egistry, discharge use of ACEIs, ARBs, or beta-blockers
ad no effect on 60- to 90-day mortality or hospitalization
ates of HFNEF patients (29,42).
As outlined in Table 4, numerous small mechanistic trials
lso reported on clinical and hemodynamic effects of phar-
acological treatment in HFNEF patients. In the after-
ath of studies reporting beneficial effects on diastolic LV
unction of calcium-channel blockers in patients with hy-
ertrophic cardiomyopathy, positive results were reported
ith verapamil in HF patients with normal LV systolic
erformance (LVEF 45%) and abnormal diastolic LV
lling (LV peak filling rate [PFR] 2.5 LVEDV/s) (43).
ositive results consisted of improvement of a clinical HF
core, treadmill exercise capacity, and LV PFR. Although
nly 22 patients participated in this trial, patient recruit-
ent was performed with great care and derived from a
creening procedure of 182 HF patients with an LVEF
45%. This screening procedure drew on earlier experience
ith HFNEF patients (44), whereby an LV PFR 2.5
VEDV/s was observed in only 38% of patients with HF
nd a normal LVEF. The hemodynamic features of the trial
opulation corresponded with concentric LV remodeling as
ymmetric LV hypertrophy, defined by a wall thickness
1.2 cm, was present in 65% of patients. In line with
oncentric LV remodeling, HF was attributed to hyperten-
ion in 75% of patients and to coronary artery disease in only
5% of patients. In contrast to this initial study, 2 subse-
uent studies on pharmacological treatment of HFNEF
atients focused on patients with limited prior myocardial
nfarctions (45,46). In this patient group, Aronow et al.
45,46) reported beneficial effects on symptoms with enalapril
nd on prognosis with propranolol. In the propranolol-treated
roup, mortality decreased by 30%. Post-myocardial infarction
atients are at risk for unfavorable eccentric LV remodeling,
nd the positive outcomes observed in these studies therefore
ave limited relevance to HFNEF patients, who usually suffer
rom concentric LV remodeling. Beneficial effects of beta-
locker therapy also were observed in a small study comparing
nrollment Criteria of HFNEF RegistriesTable 3 Enrollment Criteria of HFNEF Registries
Dobre et al.
Beta-Blockers
25 months (39)
C
Ca
1 y
HF signs and symptoms
(other criteria)
Present P
Normal LV systolic function LVEF 40% LVE
LV diastolic dysfunction —
Positive outcomes Mortality 43% Mortality 6
Use of beta-blockers also had no effect on 1-year mortality or hospitalization rates (42).
Abbreviations as in Table 1.ebivolol with atenolol (47). This study rigorously adhered to liagnostic HFNEF guidelines by requiring both an LVEF
50% and an LV end-diastolic dimension 60 mm to
stablish normal systolic LV function and by obtaining invasive
vidence of elevated PCWP. Six months of treatment resulted
n improvement of the E/A ratio and reduction in LV mass
ith both compounds. Only nebivolol, however, succeeded to
ower rest and exercise PCWP and to raise maximal oxygen
onsumption during exercise. Another small study, the
WEDIC (Swedish Doppler-Echocardiographic Study), also
sed stringent entry criteria as it determined a wall motion
core index to exclude dyskinetic segments of previous myo-
ardial infarctions and as it required evidence of age-adjusted
iastolic LV dysfunction on mitral or pulmonary venous flow
elocity Doppler (48). Six months of carvedilol therapy had no
ffect on symptomatic status; failed to alter an integrated score
f all diastolic function indexes, which was the primary end
oint of the study; but improved the E/A ratio, especially in
atients with a higher baseline heart rate. Because aldosterone
ad been implicated in myocardial fibrosis and hypertrophy,
he effects of aldosterone antagonism on myocardial
unction were investigated in hypertensive patients with
iastolic HF (New York Heart Association functional
lass II) using quantitative echocardiographic techniques
49). In the spironolactone-treated (25 mg) group, LV
ong-axis function improved with higher strain, strain rate,
nd integrated backscatter. The treated group also had
maller posterior wall thickness and LA area but unchanged
readmill exercise time. Inspired by these positive results,
arge outcome trials are currently being carried out to further
xplore the use of spironolactone in HFNEF. Their results
re expected by 2010 for the ALDO-DHF (Aldosterone
eceptor Blockade in Diastolic Heart Failure) trial and by
011 for the TOPCAT (Treatment of Preserved Cardiac
unction Heart Failure with an Aldosterone Antagonist)
rial. In experimental hypertensive HF, statins exert a
ariety of actions that may directly impact diastolic LV
ysfunction, such as regression of LV hypertrophy and
revention of myocardial fibrosis (50). These actions have
ot yet been confirmed in clinical hypertensive heart disease
r HFNEF. Nevertheless, usefulness of statins in HFNEF
as suggested in a preliminary report that showed statins to
Trial
Compound
Duration (Ref. #)
E
ol
1)
OPT-HF
ACEI, ARB, Beta-Blockers
60–90 days* (29)
Tribouilloy
ACEIs
5 years (40)
t Present Present
% LVEF 50% LVEF 50%
— —
pitalizations — Mortality 30%OHER
rvedil
ear (4
resen
F 40
—
%; hosower mortality with a relative risk reduction of 22% (51).
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February 9, 2010:526–37 Treatment of HFNEFlinical and hemodynamic features of the HFNEF patient
opulation recruited in this study suggested predominant
oncentric LV remodeling as most patients were hyperten-
ive (80%) and as LV mass was elevated (204 g). In this
tudy, other compounds, such as ACEIs, ARBs, beta-
lockers, or calcium-channel blockers, had no discernible
ffect on survival. In contrast to most other outcome or
echanistic trials, which randomized patients between
edication and placebo, the Hong Kong Diastolic Heart
ailure Study randomized HFNEF patients among diuret-
cs alone, diuretics plus ramipril, and diuretics plus irbesar-
an (52). In elderly HFNEF patients, emphasis on symp-
omatic improvement instead of survival seems justified, and
s such a comparison with diuretics instead of placebo seems
efendable. Hospitalizations and exercise tolerance changed
imilarly in all 3 groups, and addition of ramipril or
rbesartan only resulted in lower NT-proBNP levels and
igher systolic (S) and early diastolic (E=) mitral annular
elocities.
Finally, a series of smaller studies also investigated clinical
nd hemodynamic effects of pharmacological treatment in
atients with prior myocardial infarction or with arterial
ypertension who had normal LVEF and no HF. These
tudies are summarized in Table 5. Their results are of
elevance to HFNEF patients as they provide important
echanistic insight. The PREAMI (Randomized Perindo-
ril and Remodelling in Elderly With Acute Myocardial
nfarction) trial studied New York Heart Association func-
ional class I to II patients with an LVEF 40% after prior
yocardial infarction and observed less eccentric LV re-
odeling (0.7 ml vs. 4 ml LVEDV/year) when patients
ere treated with 8 mg perindopril (53). This trial is of
nterest as it revealed eccentric LV remodeling to occur even
fter small myocardial infarctions that do not compromise
aseline LV function. It also implies that inclusion of
atients with prior myocardial infarction can have a con-
ounding effect in an HFNEF trial because these patients
ill respond favorably through reduced eccentric LV re-
odeling. A low prevalence of prior myocardial infarction
30% of patients) has therefore been suggested as a good
ndicator for a correct HFNEF patient recruitment (30). In
atients with mitral flow velocity Doppler evidence of
iastolic LV dysfunction and with a hypertensive response
o exercise, losartan improved exercise tolerance and quality
f life when compared with both placebo (54) and hydro-
hlorothiazide (55). In contrast, in a similar patient popu-
ation with arterial hypertension and TDI evidence of
iastolic LV dysfunction, valsartan was not superior to
egular antihypertensive agents for improving TDI early
iastolic mitral annular lengthening velocity (E=) (56). Both
tudies are of interest because they suggested that in
FNEF trial populations with a high prevalence of arterial
ypertension, superiority needs to be established not just
ver placebo but also over regular blood-pressure-loweringtherapy.En
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Treatment of HFNEF February 9, 2010:526–37he Mismatch Between Guidelines and Trials
vidence of normal systolic LV function was defined in the
rst set of guidelines (10) as an LVEF 45% and in the 3
ost recent sets of guidelines (5,15,16) as an LVEF 50%.
he HFNEF trials or registries, however, recruited patients
hose LVEF varied from 35% to 50%, with 8 of the 21
rials or registries presented in this review using a cutoff
alue of 40% or less. Because LVEF of HF patients presents
s a unimodal distribution (57), the choice of a specific
utoff value might seem arbitrary. However, data from the
HARM program on the predictive value of LVEF for
ardiovascular outcome revealed LVEF to contribute to
ardiovascular death only when it fell below 45% (58).
ence, an LVEF 45% seems to be a logical cutoff value
or establishing a level of systolic LV function that separates
FREF from HFNEF. Furthermore, raising the LVEF
riterion above 45% increases inclusion of women into the
rial or registry because the distribution of LVEF in female
F patients peaks at 60%, whereas in male HF patients it
eaks at 35% (57).
The LV anatomy characteristically differs between HFNEF
nd HFREF, with eccentric (low mass/volume ratio) LV
emodeling in HFREF and concentric (high mass/volume
atio) LV remodeling in HFNEF (6–9). To account for
hese anatomical differences, 3 of 4 sets of guidelines
5,15,16) added an LVEDVI criterion to the requirements
or establishing normal systolic LV function in HFNEF. Of
he 21 HFNEF trials presented in this review, only 1
pecified an LV end-diastolic dimension 60 mm as an
nrollment criterion (47). In fact, several trials ended up in
he reverse situation as they promoted recruitment of
atients with eccentric LV remodeling by specifying a
ardiothoracic ratio 0.55 as an enrollment criterion
27,38). This seems understandable for V-HeFT (27),
hich identified HFNEF patients by retrospective analysis
f the V-HeFT population, but is less evident for recent
rials such as PEP-CHF (38), which specifically recruited
FNEF patients. Another patient characteristic favoring
ecruitment of patients with eccentric LV remodeling is the
Enrollment Criteria of Small Trials With Prior MITable 5 Enrollment Criteria of Small Trials W
PREAMI
Perindopril
1 year (53)
HF signs and symptoms
(other criteria)
Absent (prior MI)
Normal LV systolic function LVEF 40%
LV diastolic dysfunction —
Positive outcomes LVEDV
Enrollment criteria of small mechanistic trials in patients with prior m
LVEF and no HF.
RR2  regular blood pressure lowering therapy; other abbreviatioresence of LBBB, which was used in the I-PRESERVE drial as an enrollment criterion (2). By not rigorously
xcluding LV dilation and eccentric remodeling, many
FNEF trials ended up with a patient population in which
F was mainly of ischemic etiology. This was especially
rue in the CHARM-Preserved trial (33) and the Digitalis
nvestigation Group studies (31,32), in which HF was of
schemic etiology in respectively 56% and 70% of patients,
nd in the COHERE registry (41), which reported a 51%
revalence of coronary artery disease. To exclude patients
ith coronary artery disease and dyskinetic LV segments, an
chocardiographic wall motion score has been used as an
nrollment criterion in the PEP-CHF (38) and SWEDIC
48) trials. Such a score indeed seems a valuable adjunct to
he LVEF and LVEDVI criteria currently proposed to
stablish normal systolic LV function in patients with
FNEF.
In the 21 HFNEF trials presented in this review, the
ost frequently overlooked condition for the diagnosis of
FNEF was evidence of diastolic LV dysfunction. In fact,
nly 7 trials (38,43,47–49,55,56) required this condition to
e satisfied. The reasons for overlooking diastolic LV
ysfunction in the diagnosis of HFNEF were both concep-
ual and methodological. Initial studies on diastolic HF (44)
lready emphasized the heterogeneity of its clinical presen-
ation, with only one-third of the patients who present with
F and a normal systolic LV function also having signifi-
ant diastolic LV dysfunction evident from a depressed LV
FR on radionuclide LV angiograms. More than 2 decades
ater, the echocardiographic CHARMES substudy again
onfirmed these findings (34). Only one-half of the
HARM-Preserved trial patients, whose recruitment was
olely based on signs and symptoms of HF and an LVEF
40%, also had diastolic LV dysfunction evident from a
seudonormal or restrictive LV filling pattern on mitral flow
elocity Doppler. Furthermore, evidence of diastolic LV
ysfunction on mitral flow velocity Doppler appeared to be
idespread and aspecific as it also occurred in the elderly
atients (59) and in patients with HFREF (60). Because of
his lack of sensitivity and specificity of diastolic LV
Trior MI or HT
Trial/Authors
Compound
Duration (Ref. #)
Little et al.
osartan vs. HCTZ
6 months (55)
VALIDD
Valsartan  RR 2 vs. RR 2
38 weeks (56)
Absent
(exertional HTN)
Absent (HTN)
LVEF 50% LVEF 50%
E/A 1.0 E= 8
Symptoms —
al infarction (MI) or with arterial hypertension (HTN), who had normal
Table 1.or Hith P
L
yocardiysfunction, diastolic HF was referred to as HF with
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February 9, 2010:526–37 Treatment of HFNEFreserved LVEF (11) or as HFNEF (12). Trial design
ollowed this conceptual evolution and largely discarded
iastolic LV dysfunction as an inclusion criterion in HFNEF
rials. Recently, however, this trend again reversed because
f the appearance of superior, less load-sensitive, TDI-
erived indexes of diastolic LV dysfunction (5) and because
f growing awareness that many HFNEF patients, defined
olely by signs and symptoms of HF and normal LVEF,
ight be suffering from noncardiac illnesses. This reversal
as evident from the more recent trials such as the
ALIDD (Valsartan In Diastolic Dysfunction) (56) and
ong Kong diastolic HF trials (52), which used TDI-
erived mitral annular early diastolic lengthening velocity
E=) as an inclusion criterion or as an outcome measure,
espectively. The importance of diastolic LV dysfunction
or HFNEF was also reappraised by recent invasive
tudies in HFNEF patients, which showed uniform
resence at rest of slow LV relaxation and elevated
iastolic LV stiffness (61) and which demonstrated ele-
ated diastolic LV stiffness to limit cardiac performance
uring atrial pacing and exercise (62).
A final compelling argument for using evidence of dia-
tolic LV dysfunction as an obligatory inclusion criterion in
FNEF trials was provided by the CHARMES echocar-
iographic substudy of the CHARM-Preserved trial (34).
he CHARMES trial revealed less than one-half of the
HARM-Preserved patients to have moderate or severe
iastolic LV dysfunction. Moderate or severe diastolic LV
ysfunction was, however, an important predictor of adverse
utcomes, in both univariate and multivariate analysis with
espective hazard ratios of 3.7 and 5.7. The low event rate
bserved in the CHARM-Preserved trial was therefore
ttributed to the inclusion of numerous patients who failed
o have significant diastolic LV dysfunction. Similar to the
HARMES trial, an earlier study (44) also compared
linical characteristics of HFNEF patients with or without
iastolic LV dysfunction. In the absence of diastolic LV
ysfunction, patients mainly suffered from acute myocardial
schemia or from LV volume overload because of chronic
enal failure, hemodialysis, or unappreciated mitral regurgi-
ation, whereas in the presence of diastolic LV dysfunction,
he HF etiology was arterial hypertension in 60% of patients
nd coronary artery disease in only 27% of patients. Hence,
lthough inclusion of LVEDVI and diastolic LV dysfunc-
ion criteria would make patient enrollment into a large
utcome HFNEF trial more cumbersome and limited to a
istinct subset of patients, this drawback would largely be
ompensated by a study population with a higher prevalence
f concentric LV remodeling and a higher outcome event
ate.
oadmap for a Specific HFNEF Therapy
lthough the neutral outcomes of many HFNEF trials
ould have resulted from deficient patient enrollment crite-
ia, differences in myocardial structure and function could Plso account for the unequal outcomes of trials in HFNEF
nd HFREF (9). Future HFNEF trials should therefore
ocus on compounds that specifically interfere with struc-
ural and functional myocardial abnormalities characteristi-
ally observed in HFNEF patients. These abnormalities
nclude: 1) prominent cardiomyocyte hypertrophy; 2) break-
own and turnover of the myocardial extracellular matrix,
hich leads to concentric instead of eccentric LV remodel-
ng; 3) elevated cardiomyocyte resting tension with higher
yocardial expression and less phosphorylation of the stiff
2B titin isoform; and 4) a shift in myocardial metabolism
rom glucose to free fatty acids use because of frequent
omorbidities such as type 2 diabetes, metabolic syndrome,
nd obesity.
The LV myocardial ultrastructure in HFNEF is charac-
erized by prominent cardiomyocyte hypertrophy (9), with a
ardiomyocyte diameter 50% larger than in HFREF. This
ardiomyocyte hypertrophy parallels the LV hypertrophy
bserved in many studies or registries of HFNEF patients
6–9). Regression of myocardial hypertrophy is therefore a
eaningful therapeutic goal in HFNEF. Three HFNEF
rials thus far reported on regression of myocardial hyper-
rophy. The subanalysis of patients with LVEF 35%
ncluded in the V-HeFT reported a significant reduction in
V mass with enalapril (27). Similarly, lower LV mass was
bserved in patients treated with candesartan in the echocar-
iographic substudy of the CHARM-Preserved trial (34).
inally, in a small trial comparing atenolol with nebivolol, both
ompounds significantly reduced LVmass (47). To specifically
arget regression of myocardial hypertrophy in HFNEF,
tatins and phosphodiesterase-5 (PDE5) inhibitors both
ave been proposed recently.
By suppressing activity of the guanosine triphosphate–
inding proteins Ras, Rho, and Rac, statins can decrease
ardiomyocyte hypertrophy (63) and reduce collagen syn-
hesis (64). In a rat model of hypertensive HF, statin
reatment thereby effectively reduced LV mass both at the
tage of compensatory hypertrophy and at the stage of HF
65). The reduction of LV mass was accompanied by
educed fibrosis and lower expression of genes involved in
ardiomyocyte hypertrophy, endothelin-1 signaling, or col-
agen synthesis. In clinical HF, hemodynamic effects of
hronic statin therapy have only been reported in HFREF
atients. In one study, LV end-diastolic dimension de-
reased over a 12-month period in the atorvastatin-treated
roup but increased over the same time period in the
lacebo group. The LV mass index, however, failed to
hange in both groups (66). These findings suggest benefi-
ial clinical effects of chronic statin therapy on eccentric LV
emodeling, but not on LV hypertrophy regression, which
ould have been a more relevant finding to HFNEF.
urthermore, in another study on HFREF patients, no
ignificant LV remodeling effects of short-term (14-week)
imvastatin treatment were observed (67).
Regression of LV hypertrophy is also the target for using
DE5 inhibitors in HFNEF. In a mouse transverse aortic
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Treatment of HFNEF February 9, 2010:526–37onstriction model, the PDE5 inhibitor sildenafil reversed
re-established LV hypertrophy induced by pressure over-
oad and restored LV chamber function to normal (68). In
hese pressure-overloaded hearts, guanosine 3=,5=-cyclic mono-
hosphate (cGMP) catabolism by PDE5 was increased. Ad-
inistration of sildenafil restored cGMP levels, reactivated
rotein kinase G (PKG) activity, and deactivated multiple
ypertrophy signaling pathways such as calcineurin/nuclear
actor of activated T-cells, phosphoinositide-3 kinase/Akt, and
RK1/2. Overexpression of PDE5 was recently also observed
n the right ventricular myocardium of patients with right
entricular hypertrophy and pulmonary hypertension (69) and
n the LV myocardium of patients with end-stage HFREF
70). Regression of LV hypertrophy through restored PKG
ctivity supports the use of PDE5 inhibitors in HFNEF, and
his hypothesis is currently being tested in the RELAX
PhosphodiesteRasE-5 Inhibition to Improve Quality of Life
nd EXercise Capacity in Diastolic Heart Failure) trial.
Restored myocardial PKG activity also could directly
mprove myocardial distensibility through phosphorylation
f the giant cytoskeletal protein titin, which is responsible
or cardiomyocyte stiffness (71–73). This was confirmed in
ecent experiments using isolated cardiomyocytes of HFNEF
atients in which PKG administration resulted in a prompt
ecrease of cardiomyocyte resting tension (74,75). Correc-
ion of cardiomyocyte stiffness, unrelated to regression of
ardiomyocyte hypertrophy, could be especially relevant to
arly stages of hypertensive heart disease as suggested by the
ALIDD (Valsartan In Diastolic Dysfunction) trial, which
nly observed LV hypertrophy in 3% of asymptomatic
ypertensive patients with diastolic LV dysfunction (56).
In both HFNEF and HFREF, there is increased myo-
ardial collagen deposition but the underlying expression
atterns of matrix metalloproteinases (MMPs) and of tissue
nhibitors of matrix metalloproteinases (TIMPs), which are
esponsible for breakdown and turnover of the extracellular
atrix, are different as they are driving concentric LV
emodeling in HFNEF but eccentric LV remodeling in
FREF. In hypertensive patients with HFNEF (76) and in
atients with aortic stenosis (77), there is decreased matrix
egradation because of down-regulation of MMPs and
p-regulation of TIMPs, whereas in patients with dilated
ardiomyopathy there is increased matrix degradation be-
ause of up-regulation of MMPs (78). In patients with
ortic stenosis who develop a depressed LVEF, this balance
etween proteolysis and antiproteolysis shifts (79). These
istinct expression patterns of MMPs and TIMPs in
FNEF and HFREF result in unequal myocardial collagen
eposition with mainly interstitial fibrosis in HFNEF and
oth replacement and interstitial fibrosis in HFREF (9).
oreover, the extent of LV interstitial fibrosis also differs
etween HFNEF and HFREF. Collagen volume fraction
as lower in HFNEF than in HFREF (80), and one-third
f the patients presenting with HFNEF had a normal
ollagen volume fraction (81). Their LVEDP and LV
tiffness modulus were, however, comparable to those of iatients with an increased collagen volume fraction. This
nding suggested that in addition to collagen deposition,
ther factors also importantly contributed to the high in
ivo LV stiffness observed in HFNEF patients (81). Intrin-
ic cardiomyocyte stiffness is one of these factors. Intrinsic
ardiomyocyte stiffness is elevated in patients with HFNEF
9,81), and this mainly relates to transcriptional or post-
ranslational modifications of the cytoskeletal protein titin
73). Hence, an antiproteolytic expression pattern of MMPs
nd TIMPs, absence of replacement fibrosis, and less
nterstitial fibrosis could all explain why ACEIs and ARBs,
hich exert their beneficial action on LV remodeling partly
hrough reduction of collagen deposition, have been less
uccessful in HFNEF.
Increased diastolic LV stiffness is recognized as the
arliest manifestation of LV dysfunction induced by diabe-
es mellitus (82–84) and frequently becomes the main
unctional deficit as many diabetic patients have HFNEF
28). Excessive diastolic LV stiffness of the diabetic heart
as been related to myocardial deposition of advanced
lycation end products (AGEs). The AGE deposition
esults from long-standing hyperglycemia and affects dia-
tolic LV stiffness by direct and indirect mechanisms (85).
he AGE cross linking of collagen increases its tensile
trength, and this altered biophysical property of collagen
ncreases diastolic LV stiffness. The AGE deposition can
lso indirectly augment diastolic LV stiffness through re-
uced nitric oxide (NO) bioavailability. The AGEs quench
ndothelially produced NO, and low myocardial NO bio-
vailability raises diastolic LV stiffness (86). The importance
f the latter mechanism is supported by the preferential
ocalization of AGEs in small intramyocardial vessels as
ecently demonstrated in endomyocardial biopsies of both
iabetic HF patients (80) and elderly hypertensive dogs
87). Based on these observations, the use of AGE cross-
ink breakers such as alagebrium chloride seems promising.
small pilot study in HFNEF patients showed alagebrium
hloride to reduce LV mass, to improve LV filling, and to
meliorate quality of life (88). A similar study in hyperten-
ive subjects also showed alagebrium chloride to restore
ndothelial function (89).
Apart from myocardial AGE deposition, diabetes-related
iastolic LV dysfunction has been linked to deranged
yocardial metabolism with low myocardial phosphocre-
tine to adenosine-triphosphate ratio and high myocardial
riglyceride content. The former could be explained by
educed glucose utilization because of less-insulin-sensitive
lucose (GLUT4) transporters and the latter by increased
onesterified fatty acid fluxes (83,90). Myocardial triglycer-
de accumulation in turn leads to formation of toxic inter-
ediates, mitochondrial dysfunction, and free radical pro-
uction, which has also been linked to diabetes-related
iastolic LV dysfunction (91). Thiazolidinediones restore
lucose utilization and have recently been shown to favor-
bly modify diastolic LV dysfunction as evident from
mproved TDI mitral annular lengthening velocity (E=) (91)
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February 9, 2010:526–37 Treatment of HFNEFnd rightward displacement of the LV diastolic pressure–
olume relation (92). Such a rightward shift of the LV
iastolic pressure–volume relation could be beneficial in
iabetic HFNEF patients with concentric LV remodeling,
ut deleterious in diabetic HFREF patients, in whom it
ould exacerbate eccentric LV remodeling (93).
onclusions
n contrast to HFREF, the prognosis of HFNEF failed to
mprove over the last 3 decades, despite similar use of ACEIs,
RBs, and beta-blockers in both conditions. An urgent need
as therefore arisen for development and evaluation of novel
FNEF treatment strategies. Novel strategies should try to
nterfere with HFNEF-specific myocardial signal transduction
athways, which account for prominent cardiomyocyte hyper-
rophy, down-regulation of MMPs, up-regulation of TIMPs,
ypophosphorylation of stiff titin isoforms, and substrate shifts
rom glucose to free fatty acids. To secure correct identification
f HFNEF patients and to avoid recruitment of HFREF or
oncardiac patients, future HFNEF trials should adhere to the
roposed diagnostic guidelines for HFNEF. This implies
atient enrollment criteria to include not only a lower limit of
VEF but also an upper limit of LVEDVI and significant
vidence of diastolic LV dysfunction. Use of expanded patient
nrollment criteria is more likely to result in an HFNEF trial
opulation with concentric LV remodeling and with HF
aused by hypertension or diabetes and not by ischemic heart
isease.
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